Biosciences Research and Commercialization Center

Asalyxa Bio is a drug development and platform technology company focused on novel therapeutics to treat major unmet medical needs caused by the dysregulation of immune signaling. With applications across a wide array of disease areas and conditions, Asalyxa Bio's platform technology enables delivery of existing and novel drugs directly into over-reactive immune cells.

ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. It was founded in 2011 and is headquartered in Ann Arbor, Michigan.

Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leverages this technology to create simple surgical instrumentation, which reduces operative time and cost. Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery.

Naitive Traits develops native genetic traits that makes corn higher-yielding, resistant to drought, and tolerant of temperature extremes. Native traits have many advantages compared to genetically-engineered (GMO) traits. EaSY is the flagship product of our proprietary NT RECOVERY technology. The Company is currently negotiating licensing agreements with prominent seed companies. It was founded in 2013 and is headquartered in Kalamazoo, Michigan.

Ocuphire Pharma is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is currently focused on providing a novel once-daily eye drop treatment option, Nyxol, to treat multiple front-of-the-eye disorders, including night vision disturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

GreenMark is a healthcare company providing health-based benefits using nanoparticles. The company develops technologies that involve biopolymer nanoparticles produced from natural starch as a raw material.

Fifth Eye develops a medical device software that provides a view of a patient’s evolving hemodynamic trajectory. It enables proactive patient care to improve outcomes, avoid adverse events, shorten lengths of stay, and reduce costs.

GreenMark is a healthcare company providing health-based benefits using nanoparticles. The company develops technologies that involve biopolymer nanoparticles produced from natural starch as a raw material.

ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. It was founded in 2011 and is headquartered in Ann Arbor, Michigan.

Tetra Discovery Partners provides consulting services in drug discovery and development. They partner with Universities to commercialize intellectual property and conduct proprietary research on diseases affecting the central nervous system. Their research focuses on developing new treatments for depression and schizophrenia. Severe forms of depression affect 2–5% of the US population, while mood disorders impact 7% of the world’s population and rank among the top ten causes of disability.

Axonia Medical's proprietary approach is to repair and restore damaged peripheral or central nervous systems using tissue-engineered nerve grafts. They are expected to bridge lost nervous tissue and jump-start regenerative mechanisms to achieve levels of functional recovery not possible with current technologies.

Tetra Discovery Partners provides consulting services in drug discovery and development. They partner with Universities to commercialize intellectual property and conduct proprietary research on diseases affecting the central nervous system. Their research focuses on developing new treatments for depression and schizophrenia. Severe forms of depression affect 2–5% of the US population, while mood disorders impact 7% of the world’s population and rank among the top ten causes of disability.